Research Analysts Offer Predictions for Humana Q4 Earnings

Humana Inc. (NYSE:HUM) – Stock analysts at Zacks Research lifted their Q4 2026 earnings per share estimates for shares of Humana in a research report issued on Tuesday, July 14th. Zacks Research analyst Team now forecasts that the insurance provider will post earnings per share of ($6.07) for the quarter, up from their prior forecast of ($6.08). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $9.53 per share. Zacks Research also issued estimates for Humana’s Q4 2027 earnings at ($1.91) EPS.

Other equities analysts have also issued reports about the stock. Raymond James Financial set a $300.00 target price on shares of Humana in a report on Tuesday, July 7th. Seaport Research Partners lowered shares of Humana to a “neutral” rating in a research report on Wednesday, May 20th. Evercore upped their price objective on Humana from $250.00 to $370.00 in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, Wolfe Research raised Humana from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $325.87.

Humana Price Performance

Humana stock opened at $386.50 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $351.51 and a 200 day moving average price of $259.20. Humana has a 12-month low of $163.11 and a 12-month high of $428.88. The stock has a market cap of $46.40 billion, a P/E ratio of 41.34, a PEG ratio of 2.20 and a beta of 0.71.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, beating the consensus estimate of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The firm had revenue of $39.65 billion for the quarter, compared to analysts’ expectations of $39.37 billion. During the same quarter in the previous year, the company posted $11.58 EPS. The company’s revenue was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS.

Hedge Funds Weigh In On Humana

Hedge funds have recently made changes to their positions in the stock. Montag A & Associates Inc. lifted its stake in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares in the last quarter. CoreCap Advisors LLC boosted its position in shares of Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares during the period. Fideuram Asset Management Ireland dac acquired a new stake in shares of Humana in the fourth quarter valued at $27,000. Reflection Asset Management acquired a new stake in shares of Humana in the fourth quarter valued at $29,000. Finally, Rosenberg Matthew Hamilton raised its holdings in shares of Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Zacks Research upgraded Humana (HUM) from hold to strong-buy, signaling improving sentiment toward the stock. Zacks upgrade
• Positive Sentiment: Analysts also lifted multiple earnings estimates for Humana across 2026-2028, including FY2026, FY2027, and FY2028, which suggests expectations for stronger profitability ahead and can support valuation. Humana analyst estimates
• Positive Sentiment: Truist Financial raised its price target on Humana to $415, adding to the constructive analyst backdrop. Truist price target raise
• Neutral Sentiment: A Benzinga article discussed a Medicare weight-loss drug pricing window, which could be relevant to Humana as a managed-care provider, but the piece did not directly tie the development to HUM’s financial outlook. Benzinga Medicare article
• Neutral Sentiment: One article argued that Humana’s second-quarter earnings still need to “catch up” with the stock after a recent rally, highlighting valuation concerns rather than a new fundamental issue. Seeking Alpha article

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.